about
Subclinical Detection of Diabetic Cardiomyopathy with MicroRNAs: Challenges and PerspectivessiRNA Versus miRNA as Therapeutics for Gene SilencingApplications of mass spectrometry to the study of siRNA.Micromanaging vascular biology: tiny microRNAs play big bandIn silico identification of plant miRNAs in mammalian breast milk exosomes--a small step forward?Enterovirus71 (EV71) utilise host microRNAs to mediate host immune system enhancing survival during infection.Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma.The potential of microRNAs in personalized medicine against cancers.Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation.Effects of miR-19b overexpression on proliferation, differentiation, apoptosis and Wnt/β-catenin signaling pathway in P19 cell model of cardiac differentiation in vitro.Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.H2AX phosphorylation in response to DNA double-strand break formation during bystander signalling: effect of microRNA knockdown.Effect of miR-20b on Apoptosis, Differentiation, the BMP Signaling Pathway and Mitochondrial Function in the P19 Cell Model of Cardiac Differentiation In VitroDownregulation of microRNA-409-3p promotes aggressiveness and metastasis in colorectal cancer: an indication for personalized medicine.MiRNA inhibition in tissue engineering and regenerative medicine.Extracting microRNA-gene relations from biomedical literature using distant supervision.miR-204 inhibits invasion and epithelial-mesenchymal transition by targeting FOXM1 in esophageal cancer.Interplay of microRNAs, transcription factors and target genes: linking dynamic expression changes to function.Roles of microRNAs and their targets in cancer.Recent updates on genetics: teaching old dogmas new tricks.Effective classification of microRNA precursors using feature mining and AdaBoost algorithms.Advances with microRNAs in Parkinson's disease research.Association Between microRNA-125a rs12976445 C>T Polymorphism and 18F-Fluorodeoxyglucose (18FDG) Uptake: Clinical and Metabolic Response in Patients with Non-Small Cell Lung Cancer.Transcriptional Perturbations in Graft Rejection.MicroRNAs in neurodegenerative diseases and their therapeutic potential.Involvement of miRNA in erythroid differentiation.Noncoding RNAs in Neurodegenerative DiseasesEpigenetic studies of suicidal behavior.Baculovirus-mediated gene delivery and RNAi applications.MicroRNA expression in bone marrow-derived human multipotent Stromal cells.microRNAs and Personalized Medicine: Evaluating Their Potential as Cancer Biomarkers.Porous Silicon and Polymer Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA Therapies.Epigenetic bystander-like effects of stroke in somatic organsEffect of microRNA modulation on bioartificial muscle function.Obesity gene atlas in mammals.The new era of nanotechnology, an alternative to change cancer treatment.Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy.Transcriptional landscape and regulatory roles of small non-coding RNAs in the oxidative stress response of the haloarchaeon Haloferax volcanii.The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials.Silencing the silencer: strategies to inhibit microRNA activity.
P2860
Q26771750-F8E77202-2BEF-41F9-B092-AE5A3902045FQ26786876-56DEDDD3-FAC2-4789-B26A-329EC219CE8AQ33536680-F467B440-1498-4A71-A7CC-6ACF58D2527EQ33578296-627EDEDE-651A-4791-AB04-5CD459EE1596Q33763532-8A758F1D-63F7-4DC5-B819-9767ED60410AQ33927772-473381AE-6E4D-411D-95E2-A195B2AA7D56Q33947056-3D725851-CE3E-49F2-9E10-6D3B18A74D56Q34177547-8587EFCC-3AB3-4FF9-96F3-16825EB37D17Q34217838-7C3CB1B5-DA34-4D90-96B8-DD9EEB615AA7Q34601524-2DB618C4-47F6-4CCF-B870-0CCB8110DA1FQ34622662-D8A6E5B8-7FBD-45DA-AF72-E719A83EC6B2Q35025178-C32E3593-FCA6-4F9F-8DF6-1A179FA0DD03Q35610701-3A57A5F2-2958-4058-AD5B-B44B697C2B12Q35755274-8C40C8F3-90B5-4764-887D-2EBE43637BC8Q35799937-A16F534C-2BE2-4DF4-AD08-71A7200DE5D1Q36298235-A6BC0816-BB5D-4040-B122-818C75EC5AE4Q36375224-287B6DDD-B7AD-41A6-BE36-D7FCC91E9558Q36684786-3B30EEDC-0150-44DE-95A9-866A3520E3B8Q37012057-DAF4F34D-DE97-47F2-A943-058F9AFCED49Q37096187-02CE95CD-A159-4192-A631-D47395288571Q37139536-AD662A7B-935B-4410-A6AA-FDECD784DEC3Q37221070-2FF30675-D492-43B8-88EB-599A52C503EBQ37401474-791BB78D-ACE4-4660-BF6B-ECE4EFFE5DAAQ37573199-9FBA8C21-5D6B-43C5-BB6E-78AD5A3AF472Q37946984-D27A95BB-FE2D-425B-939F-F31B5A36A799Q37983889-B72ED729-1AA7-47BE-93B2-9A5A1505E0DCQ38112127-D3433F99-AAE1-44A5-8DEA-691437882B7DQ38183424-6D5C3AE2-4142-4082-83C2-0194DF1CE615Q38442441-D7FFDD1A-ED8A-4385-B839-9BF7C3660266Q38628576-8C466EDD-AE0F-45E6-A761-F31F5A0FF3CBQ38668239-E2A98EDB-63B7-4173-984A-74152D3AC01BQ39627292-52B3DF01-715C-49B2-B2C5-0BC99F077B2DQ39633943-5D4CE258-2262-4466-B00F-A6F85F4052CCQ39673871-C33324C7-4078-47BE-B583-93EB8A6DF785Q41854442-6AF188A8-641B-4358-B854-B2EBCD0AD49BQ42370576-5198965B-A59F-4291-8023-CABC1E866345Q44269617-3511CC90-FAE0-4BB1-9A81-1026E1525A2CQ49791507-1AC3C244-267A-45E3-A602-C5192DC4494AQ51760979-1AD0FA43-9401-4FAD-93E0-B6C87BB05906Q52608966-3D29D5DD-F857-4CD8-9204-E8C02FF5E528
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
MicroRNA gets down to business.
@en
type
label
MicroRNA gets down to business.
@en
prefLabel
MicroRNA gets down to business.
@en
P356
P1433
P1476
MicroRNA gets down to business.
@en
P2093
George S Mack
P2888
P304
P356
10.1038/NBT0607-631
P577
2007-06-01T00:00:00Z